Cyprotex launches new automated genotoxicity test
CYPROTEX, the Macclesfield-based drug testing company, said that it has added a new service line providing automated, high content screening service to detect genotoxicity.
The firm said the service uses an in-vitro mircronucleus test to analyse toxicity of genomes caused by new drug compounds. It added that the new testing method is a more cost-effective and accurate method of carrying out early-stage genotoxicity tests than existing assay methods.
The micronucleus test identifies genotoxic carcinogens, i.e., carcinogens that act by causing damage to DNA.
Dr. Katya Tsaioun, Cyprotex’s chief scientific officer, said: “Drug, cosmetic and agrichemical compounds still fail in late-stage development due to genotoxicity, at a tremendous cost to the industries.
“Consequently, as companies try to increase success rates in later stages of development, in vitro micronucleus testing, alongside other toxicity assays, is increasingly becoming a routine early-stage assay.”
Dr. Anthony Baxter, Cyprotex’s CEO, said: “Cyprotex is pleased to support pharmaceutical, cosmetic and agrichemical companies with this improved method for identifying genotoxicity during early-stage development as part of comprehensive de-risking strategy.”
